Bymetric
UK company intelligence
Company Active LTD

Company profile

Twistdx Limited

UK company 04523987, incorporated on 2 September 2002.

Versatile Isothermal DNA/RNA Amplification by TwistDx

Discover Recombinase Polymerase Amplification - The versatile PCR replacement. RPA is a rapid and robust, low temperature DNA and RNA amplification technology | TwistDx

Company number
04523987
Incorporated
2 Sep 2002
Companies House status
Active

Company identity

Founded / incorporated
2 September 2002

Company number 04523987

Verify at Companies House
Legal name
TWISTDX LIMITED
Company type
Private Limited Company
Region
South East England
Registered address
ABBOTT HOUSE VANWALL BUSINESS PARK
VANWALL ROAD
MAIDENHEAD
UNITED KINGDOM
SL6 4XE
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

2 levels 1 ultimate controller
1
Company Active LTD
Twistdx Limited
CRN 04523987
2
Direct controller Active LTD
Alere UK Holdings Limited
CRN 04267530
3
Ultimate controller
08142220
CRN 08142220

Company events

Reference milestones and recent Companies House filing stream events.

5 events
12 Jun
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

29 May
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

02 Sep
2002

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2010
Funded years
2010
Age at first award
7 years

Projects

2010 Feasibility Studies Lead participant

Feasibility of using recombinase polymerase amplification for point of care diagnosis of Mycoplasma pneumoniae a major cause of community acquired pneumonia

1 Oct 2010 to 30 Sep 2011

Awarded
£67,500
Total cost £90,000

Awaiting Public Summary

2010 Feasibility Studies Lead participant

Development of isothermal amplification method for point of care detection of classical swine fever virus african fever virus and avain influenza virus

1 Aug 2010 to 31 Oct 2011

Awarded
£75,000
Total cost £100,000

Awaiting Public Summary

2010 Feasibility Studies Lead participant

Feasibility of using recombinase polymerase amplification for a Rapid Point of Care Test for Tuberculosis

1 Aug 2010 to 31 Aug 2011

Awarded
£51,675
Total cost £74,500

Awaiting Public Summary

Product types

Feasibility Studies